Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
Filippo G. De Braud
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Research Funding - NMS; Novartis; Pfizer; Roche
Lorenzo Pilla
No relevant relationships to disclose
Monica Niger
No relevant relationships to disclose
Silvia Damian
No relevant relationships to disclose
Benedetta Bardazza
No relevant relationships to disclose
Antonia Martinetti
No relevant relationships to disclose
Giuseppe Pelosi
No relevant relationships to disclose
Giovanna Marrapese
No relevant relationships to disclose
Laura Palmeri
No relevant relationships to disclose
Giulio Cerea
No relevant relationships to disclose
Emanuele Valtorta
No relevant relationships to disclose
Silvio Veronese
No relevant relationships to disclose
Andrea Sartore-Bianchi
No relevant relationships to disclose
Elena Ardini
Employment or Leadership Position - Nerviano Medical Sciences
Marcella Martignoni
Employment or Leadership Position - Clioss
Arturo Galvani
Employment or Leadership Position - Nerviano Medical Sciences
Paul Pearson
Consultant or Advisory Role - Ignyta
Stock Ownership - Ignyta
David Luo
Employment or Leadership Position - Ignyta
Stock Ownership - Ignyta
James L. Freddo
Consultant or Advisory Role - Ignyta
Stock Ownership - Ignyta
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Roche; Sanofi
Research Funding - Bayer